Enzyme Chemistry Reagents - Medical Devices Pipeline Assessment, 2017

  • ID: 4339024
  • Report
  • 87 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Becton Dickinson and Co
  • Imperial College London
  • Nagoya University
  • MORE
Enzyme Chemistry Reagents - Medical Devices Pipeline Assessment, 2017

Summary

The author's Medical Devices sector report, “Enzyme Chemistry Reagents - Medical Devices Pipeline Assessment, 2017" provides an overview of Enzyme Chemistry Reagents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Enzyme Chemistry Reagents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Enzyme Chemistry Reagents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Enzyme Chemistry Reagents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Enzyme Chemistry Reagents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Becton Dickinson and Co
  • Imperial College London
  • Nagoya University
  • MORE
1 Table of Contents
2 Introduction
2.1 Enzyme Chemistry Reagents Overview
3 Products under Development
3.1 Enzyme Chemistry Reagents - Pipeline Products by Stage of Development
3.2 Enzyme Chemistry Reagents - Pipeline Products by Territory
3.3 Enzyme Chemistry Reagents - Pipeline Products by Regulatory Path
4 Enzyme Chemistry Reagents - Pipeline Products under Development by Companies
4.1 Enzyme Chemistry Reagents Companies - Pipeline Products by Stage of Development
4.2 Enzyme Chemistry Reagents - Pipeline Products by Stage of Development
5 Enzyme Chemistry Reagents Companies and Product Overview
5.1 Analyticon Biotechnologies AG Company Overview
5.1.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview
5.2 Becton Dickinson and Co Company Overview
5.2.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
5.3 Imperial College London Company Overview
5.3.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
5.4 Nagoya University Company Overview
5.4.1 Nagoya University Pipeline Products & Ongoing Clinical Trials Overview
6 Enzyme Chemistry Reagents- Recent Developments
6.1 Jun 14, 2017: Alere Reports First Quarter 2017 Financial Results
6.2 Jun 06, 2017: BD Releases 2016 Sustainability Report
6.3 Jun 05, 2017: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2016 Financial Results
6.4 May 22, 2017: Alere Provides Preliminary Unaudited Financial Results
6.5 May 11, 2017: Vermillion Reports First Quarter 2017 Results
6.6 May 04, 2017: PerkinElmer Announces Financial Results for the First Quarter of 2017
6.7 May 04, 2017: BioMarin Announces First Quarter 2017 Financial Results
6.8 May 02, 2017: BD Announces Results For 2017 Second Fiscal Quarter
6.9 Apr 23, 2017: BD Announces Appointment Of Tom Polen As President
6.10 Apr 19, 2017: Abbott Reports First-Quarter 2017 Results
6.11 Apr 12, 2017: Deerland Receives Globally Recognized ISO Certification For Quality
6.12 Mar 31, 2017: HORIBA Instruments commences operations at new factory in Houston
6.13 Mar 29, 2017: Vermillion Reports Fourth Quarter and Full Year 2016 Results
6.14 Mar 28, 2017: BD Announces Success of Helping Build Healthy Communities Program, Launches New Effort Focused on Medication Therapy Management
6.15 Mar 23, 2017: PerkinElmer to Display Portfolio of Cancer Research Technologies and Workflow Solutions at 2017 AACR Annual Meeting
6.16 Mar 21, 2017: Retractable Technologies Announces Litigation Updates
6.17 Mar 14, 2017: OPKO Health's GeneDx to have Significant Presence at ACMG 2017
6.18 Mar 09, 2017: Alere Provides Update on Arriva Medical
6.19 Feb 23, 2017: BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results
6.20 Feb 02, 2017: PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016
6.21 Feb 02, 2017: BD Announces Results For 2017 First Fiscal Quarter
6.22 Jan 04, 2017: Alere Laboratory Receives ABFT Accreditation
6.23 Jan 04, 2017: Alere Provides Update on Arriva Medical
6.24 Dec 28, 2016: Alere Provides Update on Arriva Medical
6.25 Dec 14, 2016: Beckman Coulter appoints IT Product Manager for Northern Europe
6.26 Dec 08, 2016: Khang & Khang Announces Securities Class Action Lawsuit against Alere and Reminds Investors with Losses to Contact the Firm
6.27 Dec 07, 2016: Abbott Seeks To Terminate Alere Acquisition
6.28 Nov 30, 2016: ARUP Laboratories appoints new CMO and director of laboratories
6.29 Nov 14, 2016: Vermillion appoints chief medical officer
6.30 Nov 10, 2016: Vermillion Reports Third Quarter 2016 Results
6.31 Nov 07, 2016: PerkinElmer Announces Financial Results for the Third Quarter of 2016
6.32 Nov 04, 2016: Alere Reports Third Quarter 2016 Financial Results
6.33 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance
6.34 Oct 27, 2016: BioMarin Announces Third Quarter 2016 Financial Results
6.35 Oct 19, 2016: Abbott Reports Third-Quarter 2016 Results
6.36 Oct 17, 2016: PerkinElmer Elects Samuel Chapin to Board of Directors
6.37 Sep 26, 2016: PerkinElmer Announces New Organizational Structure
6.38 Sep 06, 2016: Alere Reports Second Quarter 2016 Financial Results
6.39 Aug 17, 2016: Alere Reports First Quarter 2016 Financial Results
6.40 Aug 10, 2016: Vermillion Reports Second Quarter 2016 Results
6.41 Aug 08, 2016: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2015 Financial Results
6.42 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter
6.43 Aug 04, 2016: PerkinElmer Announces Financial Results for the Second Quarter of 2016
6.44 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors
6.45 Jul 27, 2016: PerkinElmer Elects Frank Witney to Board of Directors
6.46 Jul 22, 2016: Baylor Genetics rebrand makes debut with simplified name, targeted message
6.47 Jul 20, 2016: Abbott Reports Second-Quarter 2016 Results
6.48 Jul 18, 2016: BioMarin Appoints Two BioPharmaceutical Veterans to Board of Directors, Willard Dere, M.D. and Kathryn E. Falberg
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Enzyme Chemistry Reagents - Pipeline Products by Stage of Development
Table 2: Enzyme Chemistry Reagents - Pipeline Products by Territory
Table 3: Enzyme Chemistry Reagents - Pipeline Products by Regulatory Path
Table 4: Enzyme Chemistry Reagents Companies - Pipeline Products by Stage of Development
Table 5: Enzyme Chemistry Reagents - Pipeline Products by Stage of Development
Table 6: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview
Table 7: a-HBDH Fluitest - Product Status
Table 8: a-HBDH Fluitest - Product Description
Table 9: ACP/ACP - P Lyophilisat - Product Status
Table 10: ACP/ACP - P Lyophilisat - Product Description
Table 11: ALP DGKC Fluitest - Product Status
Table 12: ALP DGKC Fluitest - Product Description
Table 13: ALP IFCC Fluitest - Product Status
Table 14: ALP IFCC Fluitest - Product Description
Table 15: AMYL - CNPG3 IFCC Fluitest - Product Status
Table 16: AMYL - CNPG3 IFCC Fluitest - Product Description
Table 17: AMYL IFCC Fluitest - Product Status
Table 18: AMYL IFCC Fluitest - Product Description
Table 19: AMYL-EPS Lyophilisat - Product Status
Table 20: AMYL-EPS Lyophilisat - Product Description
Table 21: CHE Fluitest - Product Status
Table 22: CHE Fluitest - Product Description
Table 23: CK MB Fluitest - Product Status
Table 24: CK MB Fluitest - Product Description
Table 25: CK MB Lyophilisat - Product Status
Table 26: CK MB Lyophilisat - Product Description
Table 27: CK NAC Lyophilisat - Product Status
Table 28: CK NAC Lyophilisat - Product Description
Table 29: Fluitest AMYL DGKC - Product Status
Table 30: Fluitest AMYL DGKC - Product Description
Table 31: Fluitest CK NAc - Product Status
Table 32: Fluitest CK NAc - Product Description
Table 33: Fluitest CREA PAP - Product Status
Table 34: Fluitest CREA PAP - Product Description
Table 35: Fluitest GGT - Product Status
Table 36: Fluitest GGT - Product Description
Table 37: Fluitest GLDH - Product Status
Table 38: Fluitest GLDH - Product Description
Table 39: Fluitest GLU HK 100+1 - Product Status
Table 40: Fluitest GLU HK 100+1 - Product Description
Table 41: Fluitest GLU HK 5+1 - Product Status
Table 42: Fluitest GLU HK 5+1 - Product Description
Table 43: Fluitest GOT AST - Product Status
Table 44: Fluitest GOT AST - Product Description
Table 45: Fluitest GPT ALT - Product Status
Table 46: Fluitest GPT ALT - Product Description
Table 47: GGT Lyophilisat - Product Status
Table 48: GGT Lyophilisat - Product Description
Table 49: GOT AST Lyophilisat - Product Status
Table 50: GOT AST Lyophilisat - Product Description
Table 51: GPT ALT Lyophilisat - Product Status
Table 52: GPT ALT Lyophilisat - Product Description
Table 53: LDH-P Fluitest - Product Status
Table 54: LDH-P Fluitest - Product Description
Table 55: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
Table 56: BD Phoenix - Dual AST Panel - Product Status
Table 57: BD Phoenix - Dual AST Panel - Product Description
Table 58: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
Table 59: Lipase Enzymatic Assay - Product Status
Table 60: Lipase Enzymatic Assay - Product Description
Table 61: Protease Enzymatic Assay - Product Status
Table 62: Protease Enzymatic Assay - Product Description
Table 63: Transferase Enzymatic Assay - Product Status
Table 64: Transferase Enzymatic Assay - Product Description
Table 65: Nagoya University Pipeline Products & Ongoing Clinical Trials Overview
Table 66: D-Serine Assay - Product Status
Table 67: D-Serine Assay - Product Description
Table 68: Glossary

List of Figures
Figure 1: Enzyme Chemistry Reagents - Pipeline Products by Stage of Development
Figure 2: Enzyme Chemistry Reagents - Pipeline Products by Territory
Figure 3: Enzyme Chemistry Reagents - Pipeline Products by Regulatory Path
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Analyticon Biotechnologies AG
  • Becton Dickinson and Co
  • Imperial College London
  • Nagoya University
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll